首站-论文投稿智能助手
典型文献
Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern
文献摘要:
Dear Editor, As of October,2021,SARS-CoV-2 has infected more than 230 million people;promoting roll-out vaccinations could help build herd immunity for the pandemic.However,the waning of antibody in magnitude and decreased protective efficacy in multiple types of vaccines have been reported:Along with the circulating variants to some degree escaping from immune response,these led to the argument of further booster vaccination in recipients who have previously received "priming" vaccination.
文献关键词:
作者姓名:
Jingwen Ai;Haocheng Zhang;Qiran Zhang;Yi Zhang;Ke Lin;Zhangfan Fu;Jieyu Song;Yuanhan Zhao;Mingxiang Fan;Hongyu Wang;Chao Qiu;Yang Zhou;Wenhong Zhang
作者机构:
Department of Infectious Diseases,National Medical Center for Infectious Diseases,Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response,Huashan Hospital,Shanghai Medical College,Fudan University,Shanghai,China;National Clinical Research Center for Aging and Medicine,Huashan Hospital,Fudan University,Shanghai,China;Key Laboratory of Medical Molecular Virology (MOE/MOH) Shanghai Medical College,Fudan University,Shanghai,China
引用格式:
[1]Jingwen Ai;Haocheng Zhang;Qiran Zhang;Yi Zhang;Ke Lin;Zhangfan Fu;Jieyu Song;Yuanhan Zhao;Mingxiang Fan;Hongyu Wang;Chao Qiu;Yang Zhou;Wenhong Zhang-.Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern)[J].细胞研究(英文版),2022(01):103-106
A类:
B类:
Recombinant,protein,subunit,booster,following,two,dose,inactivated,vaccines,dramatically,enhanced,RBD,responses,neutralizing,titers,against,SARS,CoV,Variants,Concern,Dear,Editor, As,October,has,infected,more,than,million,people,promoting,roll,out,vaccinations,could,help,build,herd,immunity,pandemic,However,waning,antibody,magnitude,decreased,protective,efficacy,multiple,types,have,been,reported,Along,circulating,variants,some,degree,escaping,from,immune,these,led,argument,further,recipients,who,previously,received,priming
AB值:
0.802845
相似文献
An ultrapotent pan-β-coronavirus lineage B(β-CoV-B)neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
Zezhong Liu;Wei Xu;Zhenguo Chen;Wangjun Fu;Wuqiang Zhan;Yidan Gao;Jie Zhou;Yunjiao Zhou;Jianbo Wu;Qian Wang;Xiang Zhang;Aihua Hao;Wei Wu;Qianqian Zhang;Yarning Li;Kaiyue Fan;Ruihong Chen;Qiaochu Jiang;Christian T.Mayer;Till Schoofs;Youhua Xie;Shibo Jiang;Yumei Wen;Zhenghong Yuan;Kang Wang;Lu Lu;Lei Sun;Qiao Wang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences;Shanghai Institute of Infectious Disease and Biosecurity;the Fifth People's Hospital of Shanghai;Shanghai Key Laboratory of Medical Epigenetics,International Co-laboratory of Medical Epigenetics and Metabolism(Ministry of Science and Technology);Institutes of Biomedical Sciences;Biosafety Level 3 Laboratory,Shanghai Medical College,Fudan University,Shanghai 200032,China;CAS Key Laboratory of Infection and Immunity,National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing 100101,China;Experimental Immunology Branch,Center for Cancer Research,National Cancer Institute,National Institutes of Health,Bethesda,MD 20892,USA;GSK Vaccines,1300 Wavre,Belgium
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu;Qiangling Yin;Rongjuan Pei;Qiu Zhang;Yuanyuan Qu;Yongbing Pan;Lina Sun;Ding Gao;Cuiqin Liang;Jingwen Yang;Wei Wu;Jiandong Li;Zongqiang Cui;Zejun Wang;Xinguo Li;Dexin Li;Shiwen Wang;Kai Duan;Wuxiang Guan;Mifang Lian;Xiaoming Yang-National Engineering Technology Research Center for Combined Vaccines,Wuhan Institute of Biological Products Co.Ltd.,Wuhan,430070,China;State Key Laboratory for Molecular Virology and Genetic Engineering National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China;Center for Emerging Infectious Diseases,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Wuhan,430071,China;Institution of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,518107,China
Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces,China
Haisu Yi;Qian Wang;Jiankai Deng;Hengchun Li;Yingkun Zhang;Zhilong Chen;Tianxin Ji;Wenming Liu;Xuehua Zheng;Qinghua Ma;Xinxin Sun;Yudi Zhang;Xuegao Yu;Mengzhang He;Ling Chen;Ying Feng-State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,510120,China;Department of Laboratory Medicine,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou,510080,China;Center for Infection and Immunity,Guangzhou Institutes of Biomedicine and Health,Chinese Academy of Sciences,Guangzhou,510530,China;University of Chinese Academy of Science,Beijing,100049,China;Clinical Laboratory,Pingyi Hospital of Chinese Medicine,Linyi,273399,China;Xiamen Institutes of Respiratory Health,Xiamen,361013,China;Department of Respiratory and Critical Care Medicine,The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,510260,China;Guangzhou Laboratory&Bioland Laboratory,Guangzhou,510320,China
Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
Yuqi Zhu;Xinyi Yang;Jingna Xun;Jun Liu;Qing Wen;Yixiao Lin;Xiaoting Shen;Jun Chen;Songhua Yuan;Xiaying Zhao;Jing Wang;Hanyu Pan;Jinlong Yang;Zhiming Liang;Yue Liang;Qinru Lin;Huitong Liang;Min Li;Jianping Liu;Yinzhong Shen;Xiaoyan Zhang;Pengfei Wang;Daru Lu;Chunhua Yin;Jianqing Xu;Shibo Jiang;Hongzhou Lu;Huanzhang Zhu-State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology,Ministry of Education,Institute of Genetics,School of Life Sciences,Fudan University,Shanghai,200438,China;Scientific Research Center,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Fubio(Suzhou)Biomedical Technology Co.,Ltd,Suzou,215300,China;Department of Infectious Diseases and Immunology,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Fudan University,Shanghai,200032,China;Department of Infectious Diseases and Nursing Research Institution,National Clinical Research Center for Infectious Diseases,The Third People's Hospital of Shenzhen,Shenzhen,518112,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。